Schonfeld Strategic Advisors LLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Schonfeld Strategic Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.63 - $21.74 $168,243 - $207,464	-9,543 Reduced 4.21%	216,908 $4.28 Million
Q4 2023 Feb 14, 2024	BUY	$14.37 - $19.07 $257,955 - $342,325	17,951 Added 8.61%	226,451 $3.97 Million
Q3 2023 Nov 14, 2023	BUY	$13.62 - $20.2 $1.83 Million - $2.71 Million	134,070 Added 180.13%	208,500 $3.62 Million
Q2 2023 Aug 14, 2023	BUY	$10.44 - $16.48 $98,470 - $155,439	9,432 Added 14.51%	74,430 $1.05 Million
Q1 2023 May 15, 2023	BUY	$10.7 - $15.79 $160,478 - $236,818	14,998 Added 30.0%	64,998 $699,000
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $571,000 - $852,500	50,000 New	50,000 $749,000
Q3 2020 Nov 16, 2020	SELL	$15.21 - $25.53 $241,839 - $405,927	-15,900 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$15.08 - $26.0 $239,772 - $413,400	15,900 New	15,900 $405,000
Q1 2020 May 15, 2020	SELL	$11.0 - $19.76 $427,900 - $768,664	-38,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.24 - $12.96 $203,836 - $504,144	38,900 New	38,900 $430,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.